TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

David B Rosen,1 Anne Månsson Kvamnhammer,2 Burkhardt Lauffer,3 Thomas Knapp,3 Jens Jakob Karlsson,2 Enping Hong,1 Yu-Chi Lee,1 Dhruv Thakar,1 Luis Alejandro Zúñiga,1,2 Kathy Bang,1 Simran Singh Sabharwal,1 Karan Uppal,1 Janne Damm Olling,2 Kristian Kjaergaard,2 Thomas Kurpiers,3 Meike Schnabel,3 Diana Reich,3 Philipp Glock,3 Joachim Zettler,3 Mathias Krusch,3 Ana Bernhard,3 Stefan Heining,3 Valentino Konjik,3 Thomas Wegge,3 Yvonne Hehn,3 Steffen Killian,3 Laura Viet,3 Josefine Runz,3 Frank Faltinger,3 Mohammad Tabrizi,1 Kristin Laura Abel,2 Vibeke Miller Breinholt,2 Stina M Singel,4 Kennett Sprogøe,2 Juha Punnonen1

ABSTRACT

Background Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ+ natural killer (NK) cells and CD8+, CD4+ and gamma delta (γδ) T cells. However, IL-2 also potently activates immunosuppressive IL-2Rα+ regulatory T cells (Tregs) and IL-2Rα+ eosinophils and endothelial cells, which may promote VLS. Aldesleukin is rapidly cleared requiring frequent dosing, resulting in high Cmax likely potentiating toxicity. Thus, IL-2 cancer immunotherapy has two critical drawbacks: potent activation of undesired IL-2Rα+ cells and suboptimal pharmacokinetics with high Cmax and short half-life.

Methods TransCon IL-2 β/γ was designed to optimally address these drawbacks. To abolish IL-2Rα binding yet retain strong IL-2Rβ/γ activity, IL-2 β/γ was created by permanently attaching a small methoxy polyethylene glycol (mPEG) moiety in the IL-2Rα binding site. To improve pharmacokinetics, IL-2 β/γ was transiently attached to a 40kDa mPEG carrier via a TransCon (transient conjugation) linker creating a prodrug. TransCon IL-2 β/γ with sustained release of IL-2 β/γ, IL-2 β/γ was characterized in binding and primary cell assays while TransCon IL-2 β/γ was studied in tumor-bearing mice and cynomolgus monkeys.

Results IL-2 β/γ demonstrated selective and potent human IL-2Rβ/γ binding and activation without IL-2Rα interactions. TransCon IL-2 β/γ showed slow-release pharmacokinetics with a low Cmax and a long (>30 hours) effective half-life for IL-2 β/γ in monkeys. In mouse tumor models, TransCon IL-2 β/γ promoted CD8+ T cell and NK cell activation and antitumor activity. In monkeys, TransCon IL-2 β/γ induced robust activation and expansion of CD8+ T cells, NK cells and γδ T cells, relative to CD4+ T cells.

WHAT IS ALREADY KNOWN ON THIS TOPIC

- Half-life extended IL-2Rβ/γ-selective interleukin-2 (IL-2) variants have shown promise for reducing IL-2Rα-mediated toxicities, but may be limited by high Cmax-mediated effects of fully bioactive agents. Furthermore, permanent fusion to large half-life extension domains could affect IL-2 potency and/or ability for deep tumor penetration.

WHAT THIS STUDY ADDS

- This study utilizes a novel prodrug technology that provides sustained release of an IL-2Rβ/γ-selective IL-2 variant (IL-2 β/γ) containing a small polymer to block IL-2Rα binding. Importantly, IL-2 β/γ resembles endogenous IL-2 in size, sequence and IL-2Rβ/γ potency.

- On administration, the TransCon IL-2 β/γ prodrug ensures sustained release of IL-2 β/γ levels in a bioactive range for an extended period of time and with a low Cmax. This prolonged exposure of IL-2 β/γ induces durable and remarkable expansions of multiple cytotoxic immune cell types, to higher magnitudes than seen with other approaches, with minimal increases in IL-2Rα+ eosinophils and with no signs of vascular leak syndrome or cytokine release syndrome in cynomolgus monkeys.
T cells, Tregs and eosinophils, with no evidence of cytokine storm or VLS. Similarly, IL-2 β/γ enhanced proliferation and cytotoxicity of primary human CD8+ T cells, NK cells and γδ T cells.

**Summary**

TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and potential for improved clinical efficacy and tolerability compared with aldesleukin. TransCon IL-2 β/γ is currently being evaluated in a Phase 1/2 clinical trial (NCT05081609).

**BACKGROUND**

Recombinant interleukin-2 (IL-2, aldesleukin) therapy is approved for treatment of metastatic melanoma and renal cell carcinoma and elicits durable clinical responses in a subset of patients. However, major toxicities with life-threatening complications, including vascular leak syndrome (VLS), eosinophilic infiltration of cardiac and renal tissue, and cytokine release syndrome (CRS), have limited its scope of treatment. VLS is characterized by vascular damage, increased vascular permeability, leakage of fluids, proteins and electrolytes into interstitial spaces, tissue edema, hypotension and ultimately multiorgan failure that can be fatal. IL-2 activates not only cells with antitumor function, including natural killer (NK) cells, gamma delta (γδ) T cells and CD4+ and CD8+ effector T cells, but also IL-2Raα immunosuppressive regulatory T cells (Tregs) that likely limit efficacy. IL-2 can signal with picomolar affinity to trimeric IL-2Rα/β/γ or with nanomolar affinity through dimeric IL-2Rβ/γ. T cells and NK cells can upregulate IL-2Ra on activation, while Tregs constitutively express high IL-2Ra levels. Therefore, IL-2 potently activates Tregs compared with IL-2Rβ/γ CD8+ T cells, γδ T cells and NK cells that possess antitumor function. Also, IL-2 potently activates IL-2Raα eosinophils, type 2 innate lymphoid cells and endothelial cells, which may promote VLS and limit the therapeutic window. In addition to IL-2Ra engagement, another major drawback of aldesleukin therapy for cancer is its suboptimal pharmacokinetic (PK) properties with a short (85 min) elimination half-life requiring frequent, high-dose administrations resulting in high C_{max} values that likely potentiate toxicity.

While several IL-2Rβ/γ-biased IL-2 molecules designed to more preferentially activate NK cells and CD8+ T cells have been described, most approaches still have limitations such as incomplete IL-2Rβ/γ selectivity, reduced IL-2Rβ/γ potency or high C_{max}-mediated effects from delivery of fully bioactive agents. Here we describe the creation of TransCon IL-2 β/γ, a novel long-acting prodrug with sustained release of a novel receptor-selective IL-2 variant (IL-2 β/γ). Thus, TransCon IL-2 β/γ was designed using two independent approaches to optimally address the limitations of IL-2 in cancer immunotherapy, namely avoiding activation of undesired IL-2Rα cell types and poor PK properties (high C_{max} and short half-life), by achieving controlled and prolonged exposure of IL-2 β/γ to safely and robustly activate lymphocytes with antitumor function including CD8+ T cells, γδ T cells and NK cells.

Here, we describe the generation and preclinical characterization of IL-2 β/γ and the TransCon IL-2 β/γ prodrug. Active IL-2 β/γ was tested in vitro for IL-2R binding, IL-2 pathway signaling and in functional assays to assess proliferation and cytotoxic activity using primary human cells. TransCon IL-2 β/γ was evaluated in vivo in tumor-bearing mice alone and in combination with TransCon TLR7/8 Agonist, an investigational prodrug for sustained intratumoral (IT) release of the toll-like receptor (TLR)7/8 agonist resiquimod, currently in Phase 1/2 testing (NCT04799054). Lastly, the safety and pharmacodynamic (PD) profile of TransCon IL-2 β/γ was assessed in cynomolgus monkeys.

**METHODS**

**Construction of IL-2 β/γ and TransCon IL-2 β/γ**

IL-2 containing an engineered cysteine within the IL-2Rα binding region and a C125S stabilization mutation was expressed and purified from Escherichia coli or Chinese hamster ovary cells. Permanently PEGylated IL-2 variants (including IL-2 β/γ which contains a 5 kDa methoxy polyethylene glycol (mPEG) group) were constructed by selective and permanent conjugation of mPEG-maleimides of varying size to the engineered cysteine. IL-2 β/γ was further conjugated to a branched 40 kDa mPEG-linker molecule to create TransCon IL-2 β/γ (see online supplemental methods).

**Characterization of binding to human IL-2Rα or IL-2Rβ**

Biacore analysis was performed by injecting recombinant human IL-2 (hereafter referred to as control IL-2), or permanently mPEG-conjugated IL-2 variants onto human IL-2Rα-Fc (Symansis) or human IL-2Rβ-Fc (Symansis) coated sensor chips via an immobilized mouse anti-human IgG1-Fc antibody (Cytiva Life Sciences). Sensorgram data were double reference subtracted prior to affinity analyses.

**Characterization of pSTAT5 induction in primary blood cell subsets**

Cynomolgus monkey or human whole blood or human peripheral blood mononuclear cells (PBMCs), from at least two donors each, were incubated with IL-2 variants for 30 min at 37°C and then fixed (using Lyse/Fix for whole blood and 1.6% paraformaldehyde for PBMCs). Samples were analyzed by flow cytometry for signal transducer and activator of transcription 5 phosphorylation (pSTAT5) in IL-2Rα/β/γ Tregs and IL-2Rβ/γ CD8+ T cells and NK cells using methanol permeabilization...
techniques. Detailed descriptions can be found in the online supplemental methods table SM 1A-F.

**In vivo mouse tumor models**

Female BALB/c mice were inoculated subcutaneously (SC) in the right rear flank with CT26 colon carcinoma cells (American Type Culture Collection (ATCC)). Mice with established tumors (average 80–85 mm³) were untreated or treated with buffer control or TransCon IL-2 β/γ intravenously (IV) alone or in combination with IT TransCon TLR7/8 Agonist, a prodru designed for sustained release of a TLR7/8 agonist, resiquimod [22,24] as indicated in figure legends. All TransCon IL-2 β/γ dose levels are expressed in IL-2 equivalents, and all dose levels of TransCon TLR7/8 Agonist correspond to the amount of resiquimod. Additionally, mice were bled 96 hours after TransCon IL-2 β/γ dosing for flow cytometry analysis (see online supplemental methods). In some experiments, mice displaying complete responses (CR) were rechallenged with CT26 cells in the left rear flank and mice capable of rejecting a CT26 rechallenge were challenged again with CT26 cells in the left rear flank and mice capable of (see online supplemental methods). In some experiments, mice displaying complete responses (CR) were rechallenged with CT26 cells in the left rear flank and mice capable of rejecting a CT26 rechallenge were challenged again with 5×10⁵ EMT-6 tumor cells (ATCC) in the right front flank.

In the MC38 model, female C57BL/6 mice were inoculated SC with 2×10⁵ MC38 colon carcinoma cells (ATCC). Mice with established tumors (average 95 mm³) were untreated or treated with TransCon IL-2 β/γ IV and assessed for tumor growth as indicated in figure legends.

Tumor volumes were measured biweekly using a caliper and calculated as: V=(length×width²)/2. [25] For graphs and analyses of mean tumor volumes, the last measured tumor volume data from mice taken off study (eg, reaching tumor volume limits of 3000 mm³) are included in subsequent time points after euthanasia while raw data are displayed as spider plots of individual animal responses.

**Pharmacodynamic and pharmacokinetic analyses in cynomolgus monkeys**

In a first study, male cynomolgus monkeys (n=4/group) received either daily aldesleukin (0.4 mg/day on Days 1–5; average 0.044 mg/kg/day) or a single 1.0 mg TransCon IL-2 β/γ dose (average 0.122 mg/kg) IV. All TransCon IL-2 β/γ dose levels are expressed in IL-2 equivalents. As no control group was included, all data were compared with predose levels for each animal. Animals were bled at various time points after euthanasia while raw data are displayed as spider plots of individual animal responses.

In a second study, 0.1 to 0.9 mg/kg TransCon IL-2 β/γ was administered IV (slow bolus) to male and female monkeys (n=1 animal/sex/group) on Days 1 and 15. As both cycles gave similar PK/PD results, only data from the first cycle are presented. No control group was included so all data were compared with predose levels or to historical control data for anatomical pathology results. Anatomical pathology was performed on Day 29 at necropsy. Organ weights and macroscopic observations were recorded, and histopathology was performed to assess microscopic changes (see online supplemental methods). Animals were bled at various time points for PD assessment. Hematology was analyzed using a Siemens ADVIA 2120i. Immunophenotyping was performed using a Fortessa X-20 (see online supplemental methods table SM 3A, B). Serum levels of IL-5, IL-6, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1 and soluble CD25 (sCD25) were measured by immunoassays (see online supplemental methods). IL-2 β/γ plasma levels were analyzed as described above.

**In vitro human PBMC proliferation assays**

Healthy donor PBMCs (n=6) were cultured for 5 or 8 days with or without IL-2 β/γ (3.125–200 ng/mL). For the cells cultured for 8 days, culture medium with IL-2 β/γ was replenished on Day 5. Proliferation of CD8⁺ T cells, NK cells, γδ T cells and Tregs was determined by flow cytometry based on Ki67 expression as total cell count and as frequency (% of each cell type expressing Ki67).

**In vitro human lymphocyte cytotoxicity and cytokine assays**

Purified CD8, NK and γδ T cells were cultured in IL-2 β/γ (0, 50 and 200 ng/mL) for 48 hours prior to cytotoxicity assays. NK cytotoxicity assays used K562 target cells (ATCC) in a DELFIA dye release assay (Perkin-Elmer). CD8⁺ T cell cytotoxicity assays used Raji target cells (ATCC) in the presence of 1 nM of a CD3–CD20 bispecific antibody (Creative Biolabs) in a flow cytometry assay. γδ T cell cytotoxicity assays used Raji target cells as described above or Daudi target cells. Additionally, supernatants from the above cytotoxicity conditions were analyzed for cytokines and effector molecules via LEGENDplex (BioLegend) kits. For additional details see online supplemental methods.

**Statistical analyses**

The unpaired t-test was applied for data from in vivo mouse studies. No statistical analyses were performed on the monkey data due to the small number of animals per group. For in vitro conditions where the same matched samples underwent different treatment conditions, the paired t-test was applied. All statistical analyses were performed using GraphPad Prism or Microsoft Excel. A p value of <0.05 was considered statistically significant.
RESULTS

Generation of IL-2 β/γ, a potent IL-2Rβ/γ selective IL-2 variant with minimal IL-2Rα binding

To generate an optimally biased IL-2 compound, selective for IL-2Rβ/γ, several strategies were pursued. In all cases we included the C125S stabilizing mutation present in aldesleukin. Initial efforts using non-directed PEGylation with a 20kDa mPEG moiety did not achieve receptor bias and reduced potency towards IL-2Rα/β/γ and IL-2Rβ/γ (data not shown). We therefore reasoned that specific inhibition of IL-2Rα binding should be achieved by steric hindrance at the IL-2Rα binding interface. An IL-2 mutein was generated by introducing an unpaired cysteine within the IL-2Rα binding interface, and blocking mPEGs of various sizes were then permanently conjugated to this cysteine. Specifically, 2, 5, 10, 20 and 30kDa mPEG moieties were attached to test for IL-2R bias and potency effects.

To first confirm lack of IL-2Rα interactions, permanently PEGylated IL-2 muteins were characterized for IL-2Rα versus IL-2Rβ subunit binding using Biacore. While an mPEG size of 2kDa maintained some IL-2Rα interactions, mPEG sizes from 5kDa and above completely blocked the interaction with IL-2Rα (online supplemental figure S1). Within the mPEG sizes that blocked IL-2Rα (5, 10, and 20kDa mPEGs), increasing mPEG size was associated with decreasing affinity for IL-2Rβ (online supplemental figure S1), likely due to non-specific steric hindrance from the larger mPEG moieties. Based on this, a 5kDa mPEG was identified as optimal to fully block IL-2Rα interactions yet maintain IL-2Rβ potency and used to create ‘IL-2 β/γ’ (figure 1A,C).

Next, to evaluate receptor bias of IL-2 β/γ in primary human lymphocytes, pSTAT5 potency experiments were performed using whole blood or PBMCs. Compared with control IL-2, IL-2 β/γ demonstrated substantially reduced potency in Tregs while maintaining similar or slightly reduced potency in CD8+ T cells and NK cells (Treg EC50 of 34.5 vs 0.1 ng/mL; CD8+ EC50 of 62.2 vs 25.7 ng/mL; and NK cell EC50 of 11.8 vs 6.0 ng/mL for IL-2 β/γ vs control IL-2). The large potency loss seen with IL-2 β/γ in IL-2Rα/β/γ Tregs with well-maintained potency in IL-2Rβ/γ CD8+ T cells and NK cells is consistent with loss of IL-2Rα binding and IL-2Rβ/γ selectivity for IL-2 β/γ (figure 1D). In agreement with IL-2Rβ binding data, increasing mPEG size beyond 5kDa resulted in decreasing potency for induction of pSTAT5 (online supplemental figure S2) and cytotoxicity (online supplemental figure S3) in human IL-2Rβ/γ NK cells and CD8+ T cells.

Generation of TransCon IL-2 β/γ, a long-acting prodrug with sustained release of IL-2 β/γ

To improve PK properties, the TransCon IL-2 β/γ prodrug was created by transiently conjugating a branched 40kDa mPEG carrier to the receptor-selective IL-2 β/γ via the TransCon linker technology (figure 1B). This technology is similar to what is used in the long-acting TransCon Growth Hormone product, lonapegsomatropin-tcgd, and results in shielding of receptor binding and reduced renal clearance, blocking bioactivity while extending prodrug half-life. Under physiological pH and temperature, TransCon IL-2 β/γ is designed to slowly release active IL-2 β/γ from the carrier via autocleavage in a controlled manner that follows first-order kinetics.

TransCon IL-2 β/γ induced CD8+ T cell and NK cell activation and promoted antitumor efficacy in mice

Female BALB/c mice with established CT26 tumors were treated with TransCon IL-2 β/γ IV and/or TransCon TLR7/8 Agonist IT and evaluated for tumor growth inhibition and PD effects. Treatment with TransCon IL-2 β/γ alone reduced tumor volumes compared with control animals at Day 18 (1948 mm3 vs 2653 mm3, t-test p value: 0.011, figure 2A-C). At Day 14, clear antitumor efficacy was observed for treatments with TransCon TLR7/8 Agonist alone and in combination with TransCon IL-2 β/γ. At later time points the combination with TransCon IL-2 β/γ demonstrated superior efficacy compared with TransCon TLR7/8 Agonist alone (Day 25: 2226 mm3 vs 1032 mm3, t-test p value: 0.003). Similarly, treatment with the combination of TransCon IL-2 β/γ and TransCon TLR7/8 Agonist more than doubled the number of CRs (8/18) compared with TransCon TLR7/8 Agonist alone (3/18). To assess antitumor immune memory, mice with CRs from the first study were re-challenged with CT26 tumor cells. While CT26 tumors grew as expected in naive mice, all of the CR mice demonstrated rejection of the subsequent CT26 rechallenge (figure 2D). Next, these mice who rejected the CT26 rechallenge were challenged with EMT6, a distinct tumor cell line with shared neoantigens. While all mice that previously rejected CT26 rechallenge showed reduced EMT6 tumor growth compared with naive mice, mice previously treated with TransCon IL-2 β/γ and TransCon TLR7/8 Agonist completely rejected the challenge with EMT6 (figure 2E).

The antitumor effect of TransCon IL-2 β/γ was also assessed in C57BL/6 mice with established MC38 tumors. Similar to the CT26 model, a significant reduction in tumor growth was observed following treatment with TransCon IL-2 β/γ compared with control (Day 20: 1678 mm3 vs 2562 mm3, t-test p value: 0.0099, figure 2F, online supplemental figure S4).

In CT26-bearing mice, treatments containing TransCon IL-2 β/γ induced robust proliferation and expansion of NK cells and, especially after the second dose (data not shown), CD8+ T cells, as measured by Ki67 induction and total counts in the blood and spleen (figure 3A,B). Additionally, these changes corresponded with increases in the CD8/CD4 and CD8/Treg ratios (online supplemental figure S5A). Lastly, no substantial induction of PD-1 on CD4+ or CD8+ T cells was seen in the blood or spleen (data not shown).

In functional studies using in vitro stimulation with PMA and ionomycin to illustrate effector molecule potential, blood CD8+ T cells and NK cells from TransCon IL-2 β/γ treated animals showed enhanced granzyme B expression...
and IFN-γ production with highest levels mostly observed in mice treated with the combination of TransCon IL-2 β/γ and TransCon TLR7/8 Agonist (figure 3C and online supplemental figure S5B). Of note, TransCon IL-2 β/γ-mediated granzyme B induction was also seen in freshly isolated (without in vitro stimulation) peripheral NK cells and CD8+ T cells from tumor-free animals (data not shown).

TransCon IL-2 β/γ elicited robust lymphocyte expansion in cynomolgus monkeys without inducing eosinophils or systemic biomarkers for VLS in contrast to high-dose IL-2

The pharmacology of TransCon IL-2 β/γ was next investigated in cynomolgus monkeys. In vitro, cynomolgus monkey lymphocytes demonstrated almost identical IL-2Rβ/γ selectivity and pSTAT5 potency results as seen with human cells (online supplemental figure S6). To confirm IL-2Rβ/γ selectivity in vivo, monkeys were administered IV with either a daily dose of 0.4 mg (average 0.044 mg/kg) aldesleukin for 5 days or a single 1.0 mg dose of TransCon IL-2 β/γ (average 0.122 mg/kg) and assayed for hematology and blood analytes associated with systemic inflammation and vascular damage. While treatment with both TransCon IL-2 β/γ and aldesleukin increased absolute lymphocyte counts (ALC), treatment with aldesleukin, but not TransCon IL-2 β/γ, increased eosinophil counts (figure 4A). Accordingly, minimal induction of systemic inflammatory markers such as IL-5 and IL-6 were observed after treatment with TransCon IL-2
β/γ as opposed to treatment with aldesleukin (figure 4B). Similarly, in contrast to aldesleukin treatment, minimal induction of endothelial cell injury markers (E-selectin and VCAM-1) were observed in serum after treatment with TransCon IL-2 β/γ (figure 4C). PK analysis showed that while daily aldesleukin treatment for 5 days resulted in pulsatile spikes and drops in IL-2 serum levels (mean $t_{1/2}$: 1.45 hours), a single dose of TransCon IL-2 β/γ led to prolonged levels of systemic IL-2 β/γ (mean $t_{1/2}$: 32 hours) (online supplemental figure S7).

In a second study, monkeys were administered higher doses of TransCon IL-2 β/γ. While ALC increases over predose were robust (average 3.6-fold, 27.4-fold and 19.6-fold increases at 168 hours for 0.1, 0.3 and 0.9 mg/kg, respectively), eosinophil counts were minimally changed (average 1.4-fold, 1.3-fold and 3.1-fold increases at 216 hours for 0.1, 0.3 and 0.9 mg/kg, respectively) (online supplemental figure S8A). Moreover, levels of IL-5, IL-6, IFN-γ and TNF-α remained low in animals administered with up to 0.9 mg/kg of TransCon IL-2 β/γ, whereas a dose-dependent induction of MCP-1 and sCD25 was seen (online supplemental figure S8B). Doses up to 0.3 mg/kg were well tolerated with no adverse findings, but animals receiving 0.9 mg/kg showed signs of exaggerated pharmacology with, for example, subdued behavior and body weight loss. Histopathology did not reveal any signs of vascular damage, pulmonary edema or tissue necrosis indicative of VLS in any of the groups (see online supplemental results).

TransCon IL-2 β/γ induced robust expansion and proliferation of CD8+ T cells, NK cells and γδ T cells in cynomolgus monkeys

A robust expansion of CD8+ T cells (up to 23.3-fold over predose), NK cells (up to 40.5-fold), and γδ T cells (up to 728.6-fold) was observed in peripheral blood of monkeys after TransCon IL-2 β/γ administration, peaking 168–216 hour postdose and with maximum response already at the mid dose of 0.3 mg/kg (figure 5A). CD4+ T cell or Treg expansion was minimal at 0.3 mg/kg, while the 0.9 mg/kg dose induced modest increases in CD4+ T cells and Tregs (4.2-fold and 8.5-fold, respectively). The preferential expansion of cytotoxic cells over Tregs and CD4+ T cells, particularly at the 0.3 mg/kg dose, was
Figure 3  TransCon IL-2 β/γ robustly activates CD8⁺ T and NK cells in CT26 bearing BALB/C mice. (A, B) Mice were administered 72 µg (approximately 3.6 mg/kg) of TransCon IL-2 β/γ intravenously on Days 0 and 7 and/or a single 100 µg (approximately 5 mg/kg) intratumoral dose (on Day 0) of TransCon TLR7/8 Agonist. Shown (as mean±SEM with n=5 mice/group) are percentages of proliferating (Ki67⁺) CD8⁺ T cells and NK cells in the blood and spleen 96 hours after a single dose (Day 4) or two doses (Day 11) of TransCon IL-2 β/γ as well as (B) the total CD8⁺ T cell and NK cell counts after two doses. (C) Mice were administered 60 µg (approximately 3 mg/kg) of TransCon IL-2 β/γ intravenously on Days 0 and 6. Peripheral blood was drawn 96 hours after the second dose and stimulated with BD Leukocyte Activation Cocktail for 4 hours to induce cytokine production before analysis by flow cytometry. Shown are plots for the proportion of granzyme B⁺ or IFN-γ⁺ NK cells or CD8⁺ T cells (as mean±SEM with n=4 mice/group). Statistical analyses were performed using unpaired t-test. *, p<0.05; **, p<0.01; ***, p<0.001.

IFN, interferon; IL, interleukin; NK, natural killer; TLR, toll-like receptor.
clearly observed also as robust increases in CD8/Treg, NK/Treg and γδ T/Treg ratios or the corresponding CD4+ ratios (online supplemental figure S9).

Similarly, TransCon IL-2 β/γ induced robust and durable mechanistic signs of proliferative responses (measured as % Ki67+ cells) in CD8+ T cells, NK cells and γδ T cells at all dose levels. For CD4+ T cells and Tregs, a dose-dependent induction of Ki67 was observed, but the frequency of proliferating cells was much lower than for CD8+ T cells, NK cells and γδ T cells (figure 5B). Impressively, the 0.3mg/kg dose of TransCon IL-2 β/γ induced >90% Ki67+ cells in CD8+ T cells, NK cells and γδ T cells while higher doses were required to achieve a similar effect in Tregs and CD4+ T cells. Similar expansion patterns for all populations and proliferation of cells were seen after a second administration of TransCon IL-2 β/γ (data not shown).

Further analyses demonstrated that effector memory CD8+ T cells were more sensitive to TransCon IL-2 β/γ for Ki67 induction and expansion responses than total CD8+ T cells with, for example, average 53-fold versus 19-fold expansion at 0.3mg/kg (online supplemental figure S10). Effector CD8+ T cells typically express granzyme B. Accordingly, TransCon IL-2 β/γ induced robust expansion of granzyme B+ CD8+ T cells and also granzyme B+ NK and γδ T cells (online supplemental figure S11).

Pharmacokinetics of IL-2 β/γ in cynomolgus monkeys

After intravenous dosing of TransCon IL-2 β/γ, IL-2 β/γ demonstrated low Cmax values with average (monophase) half-lives ranging from 35 to 41 hours. Between 0.1 and 0.9mg/kg TransCon IL-2 β/γ, IL-2 β/γ exposure (both mean Cmax and AUC0-336h) increased generally dose proportionally (figure 5C). Of note, at 0.3mg/kg, a dose

Figure 4  TransCon IL-2 β/γ promotes robust lymphocyte expansion in cynomolgus monkeys, without inducing eosinophils, systemic endothelial cell injury or inflammatory cytokines. Male monkeys (n=4/group) were administered daily aldesleukin (0.4mg/day, average 0.044mg/kg) on Days 1–5, or a single dose of 1.0mg (average 0.122mg/kg) TransCon IL-2 β/γ. Animals were bled throughout the study for assessment of various pharmacodynamic endpoints. (A) Total lymphocytes and eosinophils are presented as counts/µL and shown as means±SEM. (B, C) Serum concentrations of IL-5, IL-6, E-selectin and VCAM-1 presented as individual responses. IL, interleukin.
with profound PD effects, the $C_{\text{max}}$ was only 99 ng/mL. A second dose of TransCon IL-2 β/γ administered 2 weeks later generated similar exposure (data not shown), suggesting minimal accumulation with no indication of anti-drug antibodies.

**IL-2 β/γ induced proliferation and cytolytic activity of human primary CD8+ T cells, NK cells and γδ T cells**

As TransCon IL-2 β/γ induced a robust expansion of CD8+ T cells, NK cells and γδ T cells in monkeys, the effects of IL-2 β/γ on proliferation and cytotoxicity of human primary cells were explored. To mimic the IL-2 β/γ $C_{\text{max}}$ in the monkey study (99 and 280 ng/mL at 0.3 and 0.9 mg/kg TransCon IL-2 β/γ, respectively), IL-2 β/γ concentrations of 50 and 200 ng/mL were tested. Human PBMCs were stimulated with or without IL-2 β/γ for 5 or 8 days then assessed for proliferation by Ki67 expression. IL-2 β/γ induced dose-dependent and time-dependent increases in the frequency (figure 6A) and numbers (data not shown) of Ki67+ CD8+ T cells, NK cells and γδ T cells. This corresponded with increases in ratios of proliferating CD8+ T cells, NK cells and γδ T cells over proliferating Tregs (figure 6B) or CD4+ T cells (data not shown).

Next, the potential of human CD8+ T cells, NK cells and γδ T cells pretreated with IL-2 β/γ to kill human tumor cells were evaluated in vitro. Initial experiments with CD8+ and γδ T cells utilized CD20+ Raji B cell target cells and a suboptimal dose of a CD3–CD20 targeting bispecific T cell engager (overnight assay), while experiments with NK...
cells used K562 target cells (4 hours assay). Pretreatment with IL-2 β/γ clearly enhanced the cytotoxic potential of these cells (figure 7A). In agreement, increased levels of TNF-α, Fas ligand (FasL), granzyme A, granzyme B and perforin were observed in supernatants from the same CD8+ T cell, NK cell and γδ T cell cytotoxicity conditions described above (figure 7B, online supplemental figures S12A-C). Additionally, IFN-γ increases were clearly seen in overnight tumor coculture supernatants with CD8+ and γδ T cells (figure 7B), and when NK cell cocultures were extended overnight (data not shown). In contrast to the robust IFN-γ levels, no substantial IL-17A induction was observed in γδ T cell cocultures treated with IL-2 β/γ (online supplemental figure S13B, C).

DISCUSSION

The major shortcomings of aldesleukin in cancer therapy are activation of IL-2Rα Tregs, endothelial cells and inflammatory eosinophils, as well as fast clearance requiring frequent high dose administrations resulting in high Cmax values. Approaches to improve IL-2’s therapeutic potential must simultaneously balance activity and tolerability. Our approach was to maintain robust, near-native IL-2Rβ/γ potency and selectivity while also extending circulation half-life and reducing Cmax.

TransCon IL-2 β/γ was designed to optimize these features by two independent and complementary approaches. First, to generate an IL-2Rβ/γ selective agonist with potent IL-2Rβ/γ binding and activity, IL-2 β/γ was created by permanent conjugation of a small 5kDa mPEG within the IL-2Rα binding site of an IL-2 mutein. A 5kDa mPEG was chosen as PEGs>5kDa led to reduced IL-2Rβ/γ binding and activation, a finding also described by others, whereas smaller mPEGs retained some IL-2Rα activity. Beyond reducing IL-2Rβ/γ activity,
larger PEG sizes could also hinder tissue distribution or access to tight cell–cell interfaces including the immunological synapse. Second, to improve PK properties, IL-2 β/γ was transiently attached to a 40 kDa mPEG carrier via a TransCon linker, shielding bioactivity and creating the TransCon IL-2 β/γ prodrug. Accordingly, at tolerable doses of TransCon IL-2 β/γ in monkeys, active IL-2 β/γ was slowly released from the mPEG carrier, leading to a low Cmax with prolonged levels of IL-2 β/γ (effective t1/2 >30 hours) capable of inducing robust PD effects.

In vitro, IL-2 β/γ demonstrated no detectable binding to human IL-2Rα, while binding to human IL-2Rβ was well maintained, as intended. Accordingly, in human pSTAT5 bioassays, IL-2 β/γ demonstrated a substantially lower potency (200–600-fold) compared with control IL-2 on IL-2Rα+ Tregs, while maintaining activity (within ~2–3-fold) on CD8+ T cells and NK cells. Furthermore, IL-2 β/γ induced proliferation and enhanced cytotoxic function in vitro in multiple human IL-2Rβ/γ cell types, including CD8+ T cells, NK cells and γδ T cells. As TransCon IL-2 β/γ is designed for systemic exposure of IL-2Rβ/γ, elimination of IL-2Rα interactions is critical for improved tolerability. In contrast, some other IL-2 prodrug approaches are designed to be activated by tumor specific proteases and still utilize wild type IL-2Rα interactions to achieve increased potency for intratumoral IL-2Rα+ activated lymphocytes, however this approach could also have increased potency for intratumoral Tregs.

In mice, TransCon IL-2 β/γ demonstrated antitumor efficacy and potentiated the induction of long-term immunological memory in combination with TransCon TLR7/8 Agonist. Further, TransCon IL-2 β/γ demonstrated robust
activation and proliferation of CD8+ T cells and NK cells over CD4+ T cells and Tregs both as monotherapy and in combination with TransCon TLR7/8 Agonist. These findings are consistent with reports of pharmacological effects in mice for several IL-2 therapies based on native IL-2RBγ interactions but lacking IL-2Rαβ expression levels. These results support combining TransCon IL-2 β/γ and TransCon TLR7/8 Agonist in the clinic and are further corroborated by their complementary biology affecting different steps in the cancer-immunity cycle. TransCon TLR7/8 Agonist activates antigen-presenting cells and enhances antigen presentation to promote activation of cytotoxic immune cells, which can be further expanded and activated by TransCon IL-2 β/γ. Moreover, clinical data with NKTR-262 (TLR7/8 agonist) and bempegaldesleukin (NKTR-214, PEGylated aldesleukin) show that the combination is well-tolerated and has PD activity.

The antitumor efficacy of TransCon IL-2 β/γ monotherapy in mice was statistically significant, while the overall tumor growth inhibition was quite modest compared with what has been reported for other IL-2 variants. Unlike cynomolgus IL-2Rs that bind human IL-2 with similar affinity/potency as the human counterparts, and unlike mouse IL-2Rαβ which maintains good affinity to human IL-2, mouse IL-2RBγ has substantially lower potency for human IL-2. Thus, high doses of TransCon IL-2 β/γ were required in mice, resulting in a narrow therapeutic window for assessing efficacy in mouse models. Additionally, multiple doses of TransCon IL-2 β/γ and higher dose levels were required in mice compared with monkeys to induce robust proliferative responses and increases in CD8+ T cell numbers.

In monkeys, a single dose of TransCon IL-2 β/γ demonstrated profound PD effects in multiple cytotoxic lymphocyte populations that lasted for at least 10 days. TransCon IL-2 β/γ increased ALC values (up to 27-fold at 0.3 mg/kg) with minimal increases in eosinophil counts, confirming IL-2RBγ selectivity, which was in stark contrast to aldesleukin that increased both. Unlike aldesleukin, TransCon IL-2 β/γ showed minimal induction of IL-5 (associated with eosinophil activation), IL-6 (classical CRS marker) and biomarkers associated with endothelial damage (E-selectin, VCAM-1) as a surrogate measure of VLS. Further, TransCon IL-2 β/γ was well-tolerated up to 0.3 mg/kg. There were no signs of CRS and no evidence of vascular damage, pulmonary edema or tissue necrosis indicative of VLS at any dose level tested after repeated dosing.

TransCon IL-2 β/γ administration to monkeys resulted in low IL-2 β/γ Cmax and one of the longest effective half-lives of an active IL-2 (t1/2 ≥30 hours) reported to our knowledge. Moreover, the Cmax of IL-2 β/γ at 0.3 mg/kg (99 ng/mL), a dose with profound PD effects, was low and in the same range as the concentration needed to stimulate IL-2RBγ/CD8+ T cells in vitro (pSTAT3 EC50: 62.2 ng/mL, online supplemental figure S6). This low Cmax and long half-life enabled uniquely prolonged bioactive IL-2 β/γ levels which likely explain why such robust PD effects at tolerable doses were observed in monkeys compared with what has been reported for other IL-2 variants. Specifically, while max PD doses of bempegaldesleukin (0.1 mg/kg) and THOR-707 (0.3 mg/kg) increased ALCs by approximately 5-fold and 4-fold, respectively, TransCon IL-2 β/γ increased CD8+ T cells by ~10-fold and NK cells by ~2.5-fold. TransCon IL-2 β/γ increased CD8+ T cells and NK cells by on average 19-fold and 26-fold, respectively. In agreement with other IL-2RBγ agonists, higher expansion was observed in effector memory compared with total CD8+ T cells (53-fold vs 19-fold at 0.3 mg/kg TransCon IL-2 β/γ, respectively), which aligns with their reported higher IL-2RBγ expression levels. Lastly, while effects on monkey γδ T cells, a cell type whose proliferative and cytolytic functions are known to be augmented by IL-2RBγ engagement, have not been reported for other IL-2 variants, ≥0.3 mg/kg of TransCon IL-2 β/γ increased γδ T cells by on average 403-fold. This is an important finding not just due to the magnitude of the expansion, but because γδ T cells possess considerable antitumor function and can recognize and kill cancer cells in an MHC-independent and neoantigen-independent manner. In vitro, IL-2 β/γ potentiated antitumor functions of human γδ T cells including tumor cell killing and production of cytotoxic molecules and IFN-γ with minimal IL-17A induction. This is significant as pro-tumorigenic roles of IL-17A-producing γδ T cells have been reported and IL-2 β/γ showed no evidence of inducing this phenotype.

Overall, TransCon IL-2 β/γ demonstrated the targeted pharmacological and PK properties of a novel IL-2 molecule and induced profound PD responses at tolerable doses. In monkeys, these responses were characterized by durable and potent expansion of multiple cytotoxic immune cell types, including CD8+ T cells, NK cells and γδ T cells, with minimal increases in eosinophils and Tregs, and with no signs of VLS or CRS. This is likely due to the complete and selective IL-2RBγ bias along with the greatly extended exposure and low IL-2 β/γ Cmax enabled by the TransCon prodrug technology. In this way, at a tolerable dose with low Cmax, TransCon IL-2 β/γ can maintain IL-2 β/γ levels in a bioactive range for an extended period of time to achieve robust and durable PD responses of cytotoxic cell types with antitumor potential. Altogether, the responses seen in monkeys are suggestive of a potentially substantial improvement in therapeutic index beyond what has been achieved by aldesleukin and could bode well for combination therapies with complementary mechanisms. In fact, IL-2 variants have been combined with anti-PD-1 therapy and have shown early encouraging clinical results. In this light, TransCon IL-2 β/γ is currently being evaluated in a clinical Phase...
1/2 trial both as a monotherapy and in combination with pembrolizumab or standard of care chemotherapy (NCT05081609).

Author affiliations
1 Ascendis Pharma Inc, Redwood City, California, USA
2 Ascendis Pharma A/S, Hellerup, Denmark
3 Ascendis Pharma GmbH, Heidelberg, Germany
4 Ascendis Pharma Inc, Palo Alto, California, USA

Acknowledgements
The authors acknowledge Minds Kjeldgaard-Hansen and Christian Krapp for critical review of the manuscript and Melany Musso, Francois J Villinger, and Jason Goetzmann from the University of Louisiana for contributions to cynomolgous monkey studies and immunophenotyping development.

Contributors
DBR, AMK, BL, TK, JJK, DGO, TK, JZ, MT, KLA, VMB, SMS, KS, and JP designed studies and performed data analysis. EH, Y-CL, DT, LAZ, KB, DBR, SSS, MS, DR, PG, MB, AH, SH, VK, TW, YH, SK, LV, JR, FF and KU performed experiments and/or analyzed data. DBR and AMK wrote the paper with contributions from all authors. DBR serves as the guarantor for this work.

Funding
These studies were funded by Ascendis Pharma.

Competing interests
All authors are or were employees and/or stockholders of Ascendis Pharma and declare competing financial interests.

Patient consent for publication
Not applicable.

Ethics approval
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
David B Rosen http://orcid.org/0000-0002-9856-7675
Luis Alejandro Zúñiga http://orcid.org/0000-0002-1832-122X

REFERENCES
1. Wrangle JM, Patterson A, Johnson CB, et al. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res 2018;38:45–68.
2. Tang A, Harding F. The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer. Cytokine 2019;11.
3. Baluna RG. Cytokine-Induced vascular leak syndrome. Cytokines in Human Health: Immunotoxicology, Pathology, and Therapeutic Applications 2007:205–31.
4. EMA. Letter of support for drug-induced vascular injury (DIVI) biomarker. EMA/641470/2017, 2017. Available: https://www.ema.europa.eu/documents/other/letter-support-drug-induced-vascular-injury-divi-biomarker_en.pdf
5. FDA. Letter of Support for Drug-Induced Vascular Injury (DIVI) Biomarker(s). 2016. Available: https://www.fda.gov/media/101684/download
6. Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014;124:110–11.
7. Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014;25:377–90.
8. Rand TH, Silberstein DS, Kornfield H, et al. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88:825–32.
9. van Haelst Pisani C, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991;78:1538–44.
10. Krieg C, Létourneau S, Pantaleo G, et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010;107:11906–11.
11. Van Gool F, Molofsky AB, Morar MM, et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 2014;124:3572–6.
12. Konrad MW, Hemstrett G, Hersh EM, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990;50:2009–17.
13. Charych DH, Hoch U, Langovski J, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res 2016;22:680–90.
14. Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One 2017;12:e0179431.
15. Ptacin JI, Caffaro CE, Ma L, et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat Commun 2021;12:4785.
16. Carmenate T, Pacios A, Enamorado M, et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013;190:6230–8.
17. Lopes JE, Fisher JL, Flick H, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer 2020;8:e000673.
18. Joseph IB, Ma L, Ptacin JL, Caffaro CE, et al. Abstract 3258: THOR-707, a novel not-alpha IL-2, elicits durable pharmacodynamic responses in non-human primates and efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models. Cancer Res 2019;79:3258.
19. MD T, Merchant F, Merchant N. MDNA11 is a long-acting IL-2 superkinase that potentiates durable immune response in mouse tumor models and non-human primates. Journal of Clinical Oncology 2021:39:e14546-e46.
20. Walkley CD, Hara P, Tatalick L, et al. Abstract 4518: Pre-clinical development of NL-201: A de novo α-independent IL-2/IL-15 agonist. Cancer Res 2020;80:4518–18.
21. Klein C, Walthauer I, Nicolin GV, et al. Cergutuzumab amunleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncimmunology 2017;6:e127708.
22. Zuniga LA, LT, Holten-Andersen L, Bisek N, et al. P676 intratumoral delivery of TransConTM TLR7/8 agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction. J Immunother Cancer 2019;7:9.
23. Mirza A, Zuniga L, Uppal K, et al. 16 tumor growth inhibition mediated by a single dose of intratumoral TransConTM TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines. J Immunother Cancer 2021;9:A18.
24. Zuniga L, Uppal K, Bang K, et al. 769 A single dose of intratumoral TransConTM TLR7/8 agonist promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition. J Immunother Cancer 2021;9:A804.
25. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:114–58.
26. Stauber DJ, Debler EW, Horton PA, et al. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006:103:2788–93.
27. Sprogøe K, Mortensen E, Karfp DB, et al. The rationale and design of Trans Con growth hormone for the treatment of growth hormone deficiency. Endocr Connect 2017;6:R171–81.
28. Kubetzko S, Sarkar CA, Plückthun A. Protein PEylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439–54.
29. FDA. Lanepagatemycin-tcgd us prescribing information, 2021. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177bl.pdf.
30. EMA. Approval of Skytropha (lonapegsomatropin-tcgd). 2022. Available: https://www.ema.europa.eu/en/documents/product-
Zhong W, Myers JS, Wang F, et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics 2020;21:2.

Bukowski JF, Morita CT, Tanaka Y, et al. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol 1995;154:998–1006.

Sharda N, Khandelwal P, Zhang L, et al. Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans. Eur J Pharm Sci 2021;165:105928.

Cartwright ANR, Griggs J, Davis DM. The immune synapse clears and excludes molecules above a size threshold. Nat Commun 2014;5:5479.

Nirschl CJ, Brodkin HR, Hicklin DJ, et al. Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression. Cancer Immunol Res 2022;10:581–96.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1–10.

Diab ACB, Bilen M, et al. Reveal: phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus Bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. J Immunother Cancer 2020;8:A1–559.

Emmerich J, Bauer M, Semana M. Abstract 1744: STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Research 2021;81:1744–44.

Merchant R, Galligan C, Munegowda MA, et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. J Immunother Cancer 2022;10:e00315.

Milla ME PJ, Caffaro C, et al. THOR-707: an engineered IL-2 for the treatment of solid tumors with superior pre-clinical efficacy and safety evidence. Journal for ImmunoTherapy of Cancer 2018;6.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 2018;6:56.

Lopes JE, Sun L, Flick HL, et al. Pharmacokinetics and pharmacodynamic effects of Nemvaleukin alfa, a selective agonist of the Intermediate-Affinity IL-2 receptor, in cyclonomegus monkeys. J Pharmacol Exp Ther 2021;379:203–10.

Xencor. Xencor Q3 2021 Investor summary (Xmab306), 2021. Available: https://investorsxencorcom/static-files/243d3a74-a45c-4796-a9c8-a2d0b44b9181

Janku F, Abdul-Karim R, Azad A, et al. Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced/metastatic solid tumors: interim results from hammer, an open-label, multicenter phase 1/2 study. Cancer Res 2021;81:LB041–LB41.

Sebestyen Z, Prinz I, Déchanet-Merville J, et al. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov 2020;19:169–84.

Park JH, Lee HK. Function of γδ T cells in tumor immunology and their application to cancer therapy. Exp Mol Med 2021;53:318–27.

Vaishampayan UN MJ, Velchet V, et al. ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (PTS) with refractory solid tumours (ARTISTRY-1). Society for medical oncology (ESMO) virtual Congress Abstract 1027MO. Annals Oncol 2020;31:S708–9.
Supplemental Figure Legends

**Figure S1.** Biacore data show that 5 kDa is the optimal mPEG size for abolishing IL-2Rα interactions yet maintaining IL-2Rβ/γ interactions. Kd values from Biacore experiments testing IL-2 muteins with varying IL-2Rα blocking mPEG sizes for binding to human IL-2Rα or IL-2Rβ.

**Figure S2.** Human PBMC data show that a 5 kDa mPEG is sufficient for abolishing IL-2Rα interactions and that larger mPEG sizes reduce IL-2 β/γ potency. Human PBMCs were stimulated with IL-2 or IL-2 variants with 5, 10, or 30 kDa mPEG moieties attached to the IL-2Rα binding interface for 30 minutes at indicated concentrations then analyzed by flow cytometry for pSTAT5 in the indicated cellular populations. Shown are (A) pSTAT5 median fluorescence intensity (MFI) titration plots and (B) EC_{50} values.

**Figure S3.** IL-2 β/γ demonstrates higher cytotoxic potency compared to IL-2 variants with larger IL-2Rα blocking mPEGs. (A) NK cell cytotoxicity responses were measured against K562 targets at a fixed E:T ration of 1.25:1 and varying concentrations of IL-2 variants attached to 5, 10 or 30 kDa IL-2Rα blocking mPEGs. Data are plotted as mean ± SEM. (B) CD8^{+} T cell cytotoxicity responses were measured against Raji targets in the presence of 1 nM CD3-CD20 bispecific antibody at a fixed E:T ration of 5:1 and varying concentrations of IL-2 muteins attached to 5, 10 or 30 kDa IL-2Rα blocking mPEGs. Data are plotted as mean ± SEM. (C) Pooled data from both donors for CD8^{+} T cell and NK cell cytotoxicity assays plotted as mean ± SEM. Statistical analyses were performed using paired t-test. *, p<0.05.
**Figure S4.** Female C57BL/6 mice with established MC38 tumors were treated with buffer control or 60 µg TransCon IL-2 β/γ on Days 0, 7 and 14 (n=20 mice/group). Individual animal tumor volumes are shown.

**Figure S5A.** TransCon IL-2 β/γ increases CD8+/CD4+ and CD8+/Treg ratios in mice. CT26 bearing BALB/C mice were administered two weekly doses of TransCon IL-2 β/γ intravenously. Peripheral blood was drawn 96 h after the first and second dose and analyzed by flow cytometry. Shown are CD8+/CD4+ and CD8+/Treg ratios from blood and spleen samples as mean ± SEM (n=5 mice/group). Statistical analyses were performed using unpaired t-test. *, p<0.05; **, p<0.01; ***, p<0.001.

**Figure S5B.** TransCon IL-2 β/γ robustly activates effector function potential in CD8+ T cell and NK cells in mice after a single dose. CT26 bearing BALB/C mice were administered two weekly 60 µg doses of TransCon IL-2 β/γ intravenously. Peripheral blood was drawn 96 h after the first dose and stimulated with BD Leukocyte Activation Cocktail for 4 h to induce cytokine production before analysis by flow cytometry. Shown are example flow cytometry plots to illustrate gating (top) and aggregate data (bottom) for the proportion of Granzyme B+ or IFN-γ+ NK cells (left) or CD8+ T cells (right) as mean ± SEM (n=3-4 mice/group). Statistical analyses were performed using unpaired t-test. *, p<0.05; ***, p<0.001.

**Figure S6.** IL-2 β/γ is IL-2Rβ/γ selective in human and cynomolgus monkey cells. Human or monkey blood was stimulated with control IL-2 or IL-2 β/γ for 30 minutes at the indicated concentrations then analyzed by flow cytometry for pSTAT5 in the indicated cellular populations. Data are shown as median fluorescence intensity (MFI) of pSTAT5 for two donors as mean ± SEM (top) and summarized as EC50 values (bottom).
**Figure S7.** TransCon IL-2 β/γ provides prolonged IL-2 β/γ systemic levels compared to pulsatile IL-2 levels seen with aldesleukin treatment. Cynomolgus monkeys were administered either 0.4 mg (average 0.044 mg/kg) per day of aldesleukin for five days or a single 1 mg dose (average 0.122 mg/kg) of TransCon IL-2 β/γ intravenously. Peripheral blood was drawn post-dosing and was analyzed for serum IL-2 levels or plasma IL-2 β/γ levels respectively. Shown are systemic IL-2 levels after aldesleukin dosing (left) or IL-2 β/γ levels as IL-2 equivalents after TransCon IL-2 β/γ dosing (right) as mean ± SEM (n=4/group).

**Figure S8.** TransCon IL-2 β/γ induces dose-dependent and robust increases in lymphocytes with minimal increases in eosinophils and induction of systemic inflammation markers in cynomolgus monkeys. Cynomolgus monkeys were bled before (predose) and at various timepoints after intravenous administration of TransCon IL-2 β/γ at 0.1, 0.3 and 0.9 mg/kg (n=1 animal/sex/group) (A) Total lymphocytes and eosinophils are presented as counts/µL and shown as mean ± SEM. (B) Serum concentrations of sCD25, IL-5, IL-6, MCP-1, IFN-γ and TNF-α are presented as mean ± SEM.

**Figure S9.** TransCon IL-2 β/γ increases the ratio of CD8+ T cells, NK cells and γδ T cells to Tregs or CD4+ T cells in cynomolgus monkeys. Cynomolgus monkeys were bled before (predose) and at various timepoints after intravenous administration of TransCon IL-2 β/γ at 0.1, 0.3 and 0.9 mg/kg (n=1 animal/sex/group). (A) Ratios of CD8+ T cells, NK cells and γδ T cells to Tregs expressed as the fold change from predose ratios and shown as mean ± SEM. (B) Ratios of CD8+ T cells, NK cells and γδ T cells to CD4+ T cells expressed as the fold change from predose ratios and shown as mean ± SEM.
**Figure S10.** TransCon IL-2 β/γ induces more potent expansion of effector memory CD8+ T cells compared to total CD8+ T cells in cynomolgus monkeys. Animals were bled before (predose) and at various timepoints after intravenous administration of TransCon IL-2 β/γ at 0.1, 0.3 and 0.9 mg/kg (n=1 animal/sex/group). (A) Fold change compared to predose counts of Total (left) and Effector Memory (right) CD8+ T cells shown as mean ± SEM. (B) Percentages of proliferating (Ki67+) cells within Total (left) and effector memory (right) CD8+ T cells shown as mean ± SEM.

**Figure S11.** TransCon IL-2 β/γ induces expansion of Granzyme B expressing CD8+ T cells, NK cells and, γδ T cells in cynomolgus monkeys. Animals were bled before (predose) and at various timepoints after intravenous administration of TransCon IL-2 β/γ at 0.1, 0.3 and 0.9 mg/kg (n=1 animal/sex/group). (A) Raw cell counts and (B) Fold change of cell counts compared to predose levels for Granzyme B expressing CD8+ T cells, NK cells and γδ T cells shown as mean ± SEM.

**Figure S12A.** IL-2 β/γ induces cytokine and cytotoxic effector molecules in human CD8+ T cells. Supernatants were taken from CD8+ T cell cocultures with Raji lymphoma cells from cytotoxicity experiments described in Figure 7 and analyzed for TNF-α, IFN-γ, FasL, Granzyme A, Granzyme B and Perforin. Data are shown over the full E:T range of the assay and displayed as mean ± SEM (n=3 donors).

**Figure S12B.** IL-2 β/γ induces cytokine and cytotoxic effector molecules in human NK cells. Supernatants were taken from NK cell cocultures with K562 erythroleukemia cells from cytotoxicity experiments described in Figure 7 and analyzed for TNF-α, IFN-γ, FasL, Granzyme A, Granzyme B and Perforin. Data are shown over the full E:T range of the assay and displayed as mean ± SEM (n=3 donors).
**Figure S12C.** IL-2 β/γ induces cytokine and cytotoxic effector molecules in human γδ T cells. Supernatants were taken from γδ T cell cocultures with Raji lymphoma cells from cytotoxicity experiments described in Figure 7 and analyzed for TNF-α, FasL, IL-17A, IFN-γ, Granzyme A, Granzyme B, Perforin and Granulysin. Data are shown over the full E:T range of the assay and displayed as mean ± SEM (n=2 donors).

**Figure S13.** IL-2 β/γ induces cytokine and cytotoxic effector molecules in endogenous TCR ligand activated human γδ T cells. γδ T cells were cocultured overnight with Daudi lymphoma cells. (A) γδ T cell cytotoxicity results against Daudi target cells after subtracting for background seen in conditions with targets alone. Pooled data are expressed as mean ± SEM (n=3 donors). (B, C) Supernatants were taken from γδ T cell and Daudi cocultures described in (A) and analyzed for TNF-α, FasL, IL-17A, IFN-γ, Granzyme A, Granzyme B, Perforin, and Granulysin. (B) Fold change values at an E:T ratio of 2.0. (C) Data over the full E:T range of the assay displayed as mean ± SEM (n=2 donors for all E:Ts except E:T = 8 where n=1 due to insufficient sample).
Figure S1: Biacore data suggests 5 kDa is the optimal size for abolishing IL-2R\(\alpha\) interactions yet maintaining IL-2R\(\beta/\gamma\) interactions

| Size of biasing PEG residue | Biacore analysis (Kd values) |
|-----------------------------|-----------------------------|
|                             | Binding towards IL-2R\(\alpha\) | Binding towards IL-2R\(\beta\) |
| NA (IL-2 control)           | 9.3 nM                       | 280 nM                        |
| 2 kDa                       | 700 nM                       | 670 nM                        |
| 5 kDa                       | > 2,000 nM                   | 1,000 nM                      |
| 10 kDa                      | > 2,000 nM                   | 1,900 nM                      |
| 20 kDa                      | > 3,000 nM                   | 4,500 nM                      |

No detectable binding towards IL-2R\(\alpha\)
Figure S2: PBMC data show that a 5 kDa PEG is sufficient for abolishing IL-2Rα interactions and increasing PEG length reduces IL-2 β/γ potency.

A) Size of biasing PEG residue

B) pSTAT5 EC50 potency analysis (Human PBMCs)

| Size of biasing PEG residue | CD8+ T cells  | NK cells   | Tregs      |
|-----------------------------|---------------|------------|------------|
| NA (IL-2 control)           | 48.75 ng/ml   | 13.06 ng/ml| < 0.1 ng/ml|
| 5 kDa                       | 148.31 ng/ml  | 28.41 ng/ml| 105.47 ng/ml|
| 10 kDa                      | 242.50 ng/ml  | 49.41 ng/ml| 162.87 ng/ml|
| 30 kDa                      | 802.17 ng/ml  | 192.25 ng/ml| 432.88 ng/ml|
Figure S3: IL-2 β/γ demonstrates higher cytotoxic potency compared to IL-2 variants with larger PEG lengths

A) NK cells

Fixed E:T = 1.25:1 with K562 Erythroleukemia Targets 4h assay

B) CD8⁺ T cells

Fixed E:T = 5:1 with Raji B cell Lymphoma Targets + CD3-CD20 BsAb 20h assay

C) Pooled NK cell data

Pooled CD8⁺ T cell

* p < 0.05 for paired T test vs 5 kDa PEG

IL-2 β/γ (5 kDa PEG) enhances NK and CD8⁺ T cell cytotoxicity more potently than variants with larger blocking PEGs
Figure S4: TransCon IL-2 β/γ shows anti-tumor effects in MC38 tumor bearing mice

MC38 (individual mouse responses)
Figure S5A: TransCon IL-2 β/γ increases CD8⁺/CD4⁺ and CD8⁺/Treg ratios in mice

**Blood**

| Condition                        | CD8 / CD4 Ratio | CD8 / Treg Ratio |
|----------------------------------|-----------------|------------------|
| Untreated                        |                 |                  |
| TransCon IL-2 β/γ               |                 |                  |
| TransCon TLR7/8 Agonist          |                 |                  |
| TransCon IL-2 β/γ + TransCon TLR7/8 Agonist |             |                  |

**Spleen**

| Condition                        | CD8 / CD4 Ratio | CD8 / Treg Ratio |
|----------------------------------|-----------------|------------------|
| Untreated                        |                 |                  |
| TransCon IL-2 β/γ               |                 |                  |
| TransCon TLR7/8 Agonist          |                 |                  |
| TransCon IL-2 β/γ + TransCon TLR7/8 Agonist |             |                  |

Figure S5B: TransCon IL-2 β/γ robustly activates effector function potential in CD8⁺ T and NK cells in mice

**Example Gating**

**NK cells**

- **Control**
  - Granzyme B⁺
  - IFN-γ⁺

- **TransCon IL-2 β/γ**
  - Granzyme B⁺
  - IFN-γ⁺

**CD8⁺ T cells**

- **Control**
  - CD44⁺
  - IFN-γ⁺

- **TransCon IL-2 β/γ**
  - CD44⁺
  - IFN-γ⁺
Figure S6: IL-2 $\beta/\gamma$ is IL-2R$\beta/\gamma$ selective in human and cynomolgus monkey cells

Summary of pSTAT5 Potency Values in Human and Cynomolgus Monkey Blood

|                  | Treg  | CD8$^+$ T | NK     |
|------------------|-------|-----------|--------|
| **EC$_{50}$ (ng/mL)** |       |           |        |
| Human            |       |           |        |
| IL-2             | 0.09  | 25.69     | 6.01   |
| IL-2 $\beta/\gamma$ | 34.50 | 62.15     | 11.84  |
| Cynomolgus Monkey|       |           |        |
| IL-2             | 0.09  | 45.10     | 10.52  |
| IL-2 $\beta/\gamma$ | 52.16 | 86.4      | 16.26  |
Figure S7: TransCon IL-2 $\beta/\gamma$ provides stable IL-2 $\beta/\gamma$ systemic levels compared to pulsatile IL-2 levels seen with aldesleukin treatment.

Open circles on D2, D3, D4 represent data inputed based on the average 15’ post dose data from D1 and D5

Dashed lines indicate dosing occasions
Figure S8: TransCon IL-2 β/γ, at ascending doses, induces robust lymphocyte responses with minimal eosinophilia and induction of systemic inflammation markers in cynomolgus monkeys.
Figure S9: TransCon IL-2 β/γ increases the ratio of CD8+ T cells, NK cells and γδ T cells to Tregs or CD4+ T cells in cynomolgus monkeys.
Figure S10: TransCon IL-2 β/γ induces more potent expansion of effector memory CD8+ T cells compared to total CD8+ T cells in cynomolgus monkeys.

A) Total CD8+ T cells

B) Effector Memory CD8+ T cells

TransCon IL-2 β/γ

- 0.1 mg/kg
- 0.3 mg/kg
- 0.9 mg/kg

Ki67+ cells (%)

Predose, 24 h, 96 h, 120 h, 168 h, 216 h, 336 h
Figure S11: TransCon IL-2 β/γ induces expansion of Granzyme B expressing CD8+ T cells, NK cells and, γδ T cells.

**TransCon IL-2 β/γ Dose**

- **0.1 mg/kg**
- **0.3 mg/kg**
- **0.9 mg/kg**

### A) CD8+ Grzyme B+ T cells

- **Predose**
- 0
- 5000
- 10000
- 15000

### B) CD8+ Grzmye B+ T cells

- **Fold change over predose**
- 0
- 20
- 40
- 60
- 80

### NK Grzmye B+ cells

- **Cell Count / uL**
- 0
- 5000
- 10000
- 15000

### γδ Grzmye B+ T cells

- **Cell Count / uL**
- 0
- 5000
- 10000
- 15000

### γδ Grzmye B+ T cells

- **Fold change over predose**
- 0
- 20
- 40
- 60
- 80
Figure S12A: IL-2 β/γ induces cytokine and cytotoxic effector molecules in human CD8+ T cells

Overnight supernatants from Raji co-culture + CD3-CD20 TCR stimulus

- TNF-α
- FasL
- IFN-γ
- Granzyme A
- Granzyme B
- Perforin

Untreated 50 ng/mL IL-2 β/γ 200 ng/mL IL-2 β/γ

Figure S12B: IL-2 β/γ induces cytokine and cytotoxic effector molecules in human NK cells

4h supernatants from K562 co-culture

- TNF-α
- FasL
- IFN-γ
- Granzyme A
- Granzyme B
- Perforin

IFNγ induction only seen after overnight coculture (data not shown)

Untreated 50 ng/mL IL-2 β/γ 200 ng/mL IL-2 β/γ
Figure S12C: IL-2 β/γ induces cytokine and cytotoxic effector molecules in human γδ T cells

Overnight supernatants from Raji co-culture + CD3-CD20 TCR stimulus
Figure S13 IL-2 β/γ induces cytotoxicity and cytokine production in endogenous TCR ligand activated human γδ T cells (Daudi coculture)

A) γδ T Cytotoxicity

B) γδ T Effector Molecules

C) Untreated 50 ng/mL IL-2 β/γ 200 ng/mL IL-2 β/γ
Supplemental Methods (SM)

Construction of IL-2 β/γ and TransCon IL-2 β/γ

IL-2 containing an engineered cysteine within the IL-2Rα binding region and a C125S stabilizing mutation was produced recombinantly in *E. coli* or CHO cells. For *E. coli*, the IL-2 mutein was harvested from inclusion bodies and refolded, then purified by size exclusion and ion-exchange chromatography. For CHO, cell culture clarification was performed by depth filtration and the IL-2 mutein was purified by chromatographic and filtration techniques. After purification of the IL-2 mutein and mild reduction with tris (2-carboxyethyl) phosphine, a 5 kDa mPEG-maleimide was selectively and permanently attached to the engineered cysteine within the IL-2Rα binding region followed by a basic incubation step to give IL-2 β/γ, which was either purified (for *in vitro* studies) or conjugated to a branched 40 kDa mPEG-Linker molecule to create the TransCon IL-2 β/γ prodrug. Subsequently, TransCon IL-2 β/γ was purified by chromatography. Similar methods were applied in earlier studies to generate bioactive IL-2 variants conjugated to mPEGs of varying lengths to determine the optimal mPEG length at the engineered cysteine to abolish IL-2Rα interactions yet maintain IL-2Rβ/γ binding and activity.

*pSTAT5 analysis from whole blood*

The following antibodies and gating definitions were used for pSTAT5 blood analyses. All subsets were analyzed for median fluorescence intensities (MFI) of pSTAT5 and half maximal effective concentration (EC$_{50}$) values were calculated for each compound across all cell types.
### Table SM 1A: Human blood pSTAT5 analysis flow cytometry reagents

| Antibody | Color | Cat. #  | Clone   | Vendor       |
|----------|-------|---------|---------|--------------|
| CD3      | BV786 | 300472  | UCHT1   | Biolegend    |
| CD25     | Biotin| 356124  | M-A251  | Biolegend    |
| CD8      | BUV805| 612889  | SK1     | BD           |
| CD56     | BV711 | 318336  | HCD56   | Biolegend    |
| CD16     | BV711 | 302044  | 3G8     | Biolegend    |
| CD4      | BUV737| 612748  | SK3     | BD           |
| CD15     | PE CY7| 323030  | W6D3    | Biolegend    |
| Streptavidin | PECY7 | 323030 | N/A     | Biolegend    |
| STAT5    | AX647 | 562076  | 47/Stat5 (pY694) | BD |
| Foxp3    | PE    | 320208  | 259D    | Biolegend    |

### Table SM 1B: Human blood gating definitions for pSTAT5 analysis:

| Population | Lymphocyte Gating Definition |
|------------|-------------------------------|
| NK cells   | CD15- CD3- CD56/CD16+         |
| Tregs      | CD15- CD3+ CD4+ CD25+ Foxp3+  |
| CD8 T cells| CD15- CD3+ CD8+              |

### Table SM 1C: Cynomolgus monkey blood pSTAT5 flow cytometry reagents

| Antibody | Color | Cat. #  | Clone   | Vendor       |
|----------|-------|---------|---------|--------------|
| CD3      | AX700 | 557917  | SP34-2  | BD           |
| CD4      | BV711 | 317440  | OKT4    | Biolegend    |
| CD7      | BV510 | 563650  | M-T701  | BD           |
| CD8      | BUV805| 612889  | SK1     | BD           |
| CD14     | BV785 | 301840  | M5E2    | Biolegend    |
| CD11b    | BV785 | 301346  | ICRF44  | Biolegend    |
| CD16     | BUV737| 612786  | 3G8     | BD           |
| CD20     | BV785 | 302356  | 2H7     | Biolegend    |
| CD25     | Biotin| 356124  | M-A251  | Biolegend    |
| Streptavidin | BUV395 | 564176 | N/A     | BD           |
| STAT5    | AX647 | 612599  | 47/Stat5 (pY694) | BD |
| Foxp3    | PE    | 320208  | 259D    | Biolegend    |
Table SM 1D: Cynomolgus monkey gating definitions for pSTAT5 analysis:

| Population | Lymphocyte Gating Definition |
|------------|-----------------------------|
| NK cells   | CD11b- CD14- CD20- CD3- CD16+ CD7+ |
| Tregs      | CD11b- CD14- CD20- CD3+ CD4+ CD25+ Foxp3+ |
| CD8 T cells| CD11b- CD14- CD20- CD3+ CD8+ |

**pSTAT5 analysis from PBMCs**

The following antibodies and gating definitions were used for pSTAT5 PBMC analyses. All subsets were analyzed for MFI of pSTAT5 and EC$_{50}$ values were calculated for each compound across all cell types.

Table SM 1E: Human PBMC pSTAT5 flow cytometry reagents

| Antibody | Color | Cat. # | Clone       | Vendor   |
|----------|-------|--------|-------------|----------|
| Foxp3    | AF488 | 320112 | 206D        | Biolegend |
| CD45RA   | PE    | 304108 | HI100       | Biolegend |
| STAT5    | AX647 | 562076 | 47/Stat5 (pY694) | BD       |
| CD8      | AX700 | 301028 | RPA-T8      | Biolegend |
| CD4      | BV421 | 300532 | RPA-T4      | Biolegend |
| CD16     | BV570 | 302036 | 3G8         | Biolegend |
| CD3      | BV605 | 300460 | UCHT1       | Biolegend |
| CD56     | BV711 | 362542 | 5.1H11      | Biolegend |
| CD25     | BV785 | 356140 | M-A251      | Biolegend |

Table SM 1F: Human PBMC gating definitions for pSTAT5 analysis:

| Population | Lymphocyte Gating Definition |
|------------|-----------------------------|
| NK cells   | CD3- CD56+                  |
| Tregs      | CD3+ CD4+ CD25+ Foxp3+     |
| CD8 T cells| CD3+ CD8+                   |

All subsets were analyzed for MFI of pSTAT5 and EC$_{50}$ values were calculated for each compound across all cell types.
Additional ARRIVE (Animal Research: Reporting of In Vivo Experiments) details for mouse experiments

Mouse tumor experiments were performed inoculating approximately double the number of mice to be enrolled in the study (as indicated in figure legends) in order to meet pre-dose target tumor volume average and range. Mice were randomized and enrolled into the study using the Matched Distribution method for randomization in the StudyLog™ software. 8-10 animals per treatment condition were used to assess efficacy in order to overcome the expected variability in syngeneic mouse tumor studies while still minimizing the number of animals used. To minimize potential confounding effects, treatments with similar agents were performed together, measurements for tumor volumes and body weights were performed in a consistent order (by treatment group), and animals were all housed in the same room. The studies were not run in a blinded fashion. CT26 experiments used naïve healthy female BALB/c mice sourced by Crown Bioscience, China or purchased from Taconic Biosciences (USA). MC38 experiments used naïve healthy female C57BL/6 mice purchased from The Jackson Laboratory (Jax, USA). Mouse work was performed at Ascendis Inc, Redwood City CA (California Department of Public Health Certificate 081) or at Crown Bioscience, Taicang City, China (Animal use permit number: AN-1903-05-1067). Mouse work at Ascendis Pharma was reviewed and approved by the Ascendis Inc. Redwood City Institutional Animal Care and Use Committee (IACUC) (Protocol 20200507-ASN-02 and Study Reference VIV-M-032) and performed in accordance with the US Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals and the USDA Animal Welfare Act. Mouse work at Crown Bioscience was approved by the Crown Bioscience IACUC (Study Reference E4649-U1920, approval reference AN-1903-05-1067) and performed in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
**Flow cytometry analysis in CT26 mouse experiments**

In the first experiment, blood was stimulated in vitro with Leukocyte Activation Cocktail, with BD GolgiPlug™ (BD Biosciences) for 5 hours at 37°C before FACS staining and acquisition on a BD Fortessa flow cytometer. Cells were preincubated with Fc-Block prior to surface staining then underwent RBC lysis (Bio-gems). Cells were then fixed and permeabilized (eBiosciences, Foxp3 kit) and stained with intracellular antibodies. In some experiments, cells were acquired in the presence of 123count Ebeads (eBiosciences), and in others, cells were acquired in a fixed volume to enable cell count calculations. In the 96 h post-dose data from this experiment there was one data point from the control group and one data point from the TransCon IL-2 β/γ group which were deemed to be technical outliers and excluded based on the questionable quality of the flow cytometry data observed.

In the second experiment, blood and spleen were harvested. Blood was lysed with 1X RBC lysis buffer (Bio-gems) and single cell suspensions for spleen were prepared by established methods. Cells were stained for surface antigens together with Fc-Block (purified anti-mouse CD16/CD32, eBioscience), then fixed and permeabilized (Foxp3 / Transcription Factor Staining Buffer Set, eBioscience) and stained with intracellular antibodies. Cells were acquired on an Agilent NovoCyte Quanteon flow cytometer, using a fixed volume to enable cell count calculations. The following antibodies and gating definitions were applied:
Table SM 2A: Flow cytometry reagents for analysis of CT26 bearing mice (first experiment)

| Markers | Fluorochrome | Cat #   | Clone   | Vendor        |
|---------|--------------|---------|---------|---------------|
| CD45    | BV711        | 103147  | 30-F11  | Biolegend     |
| CD3     | BUV395       | 740268  | 17A2    | BD Bioscience |
| CD4     | BUV737       | 564298  | GK1.5   | BD Bioscience |
| CD8     | FITC         | 100706  | 53-6.7  | eBioscience   |
| CD25    | BV510        | 102041  | PC61    | Biolegend     |
| CD335   | BV605        | 137619  | 29A1.4  | Biolegend     |
| CD44    | BV421        | 103040  | IM7     | Biolegend     |
| Ly6C    | BV785        | 128041  | HK1.4   | Biolegend     |
| CTLA4   | PE           | 106306  | UC10-4B9| Biolegend     |
| Foxp3   | PerCP-Cy 5.5 | 45-5773-82 | FJK-16S | eBioscience   |
| TNF-α   | APC          | 506308  | MP6-XT22| Biolegend     |
| IFN-γ   | PE-Cy7       | 25-7311-41 | XMG1.2 | eBioscience   |
| GranzymeB| PE-eFlour 610| 61-8898-82 | NGZB   | eBioscience   |
| Live / Dead | eFluor 780 | 65-0865-18 | NA     | eBioscience   |

Table SM 2B: Populations analyzed used in CT26 tumor bearing mice (first experiment)

| Population | Lymphocyte Gating Definition |
|------------|------------------------------|
| NK cells   | CD45+ CD3- NKp46+            |
| Tregs      | CD45+ CD3+ CD4+ CD25+ Foxp3+|
| CD4 T cells| CD45+ CD3+ CD4+             |
| CD8 T cells| CD45+ CD3+ CD8+             |
Table SM 2C: Flow cytometry reagents for analysis of CT26 bearing mice (second experiment)

| Markers | Fluorochrome | Cat #       | Clone | Vendor      |
|---------|--------------|-------------|-------|-------------|
| Ki67    | AF488        | 558616      | B56   | BD          |
| CD3e    | PerCP-eF710  | 46-0033-82  | eBio500A2 | eBioscience |
| CD25    | APC          | 17-0251-82  | PC61.5 | eBioscience |
| CD8     | AX700        | 56-0081-82  | 53-6.7 | eBioscience |
| CD45    | APC-eF780    | 47-0451-82  | 30-F11 | eBioscience |
| Foxp3   | PE           | 12-5773-82  | FJK-16s | eBioscience |
| NKp46   | PE-eF610     | 61-3351-82  | 29A1.4 | eBioscience |
| CD19    | PE-Cy5       | 115510      | 6D5   | Bioreagent  |
| CD62L   | PE-Cy7       | 25-0621-82  | MEL-14 | eBioscience |
| Granzyme B | Pacific Blue | 515408     | GB11  | Bioreagent  |
| CD11b   | BV570        | 101233      | M1/70 | Bioreagent  |
| ICOS    | BV605        | 313538      | C398.4A | Bioreagent |
| CD4     | BV650        | 100469      | GK1.5 | Bioreagent  |
| PD-1    | BV711        | 748265      | RMP1-30 | BD         |
| CD44    | BV785        | 103059      | IM7   | Bioreagent  |
| Live/Dead | eFluor 506  | 65-0866-14  | NA    | eBioscience |

Table SM 2D: Populations analyzed used in CT26 tumor bearing mice (second experiment)

| Population | Lymphocyte Gating Definition |
|------------|------------------------------|
| NK cells   | CD45+ CD19- CD3- NKp46+      |
| Tregs      | CD45+ CD19- CD11b- CD3+ CD4+ CD25+ Foxp3+ |
| CD4 T cells | CD45+ CD19- CD11b- CD3+ CD4+ |
| CD8 T cells | CD45+ CD19- CD11b- CD3+ CD8+ |

**ARRIVE (Animal Research: Reporting of In Vivo Experiments) details for cynomolgus monkeys**

The studies were performed in Mauritian cynomolgus monkeys. Due to the small number of animals, no blinding or randomization was performed. Two to four animals per group was regarded
as sufficient to assess toxicity and/or PK/PD effects, while minimizing animal usage, see details for each study below. No animals were excluded from analysis.

The first studies testing aldesleukin (Study Reference 8713-1903) and TransCon IL-2 β/γ (Study Reference 8713-1904) were performed at the University of Louisiana at Lafayette New Iberia Research Center (NIRC), Lafayette, USA (USDA Animal Welfare Act Certificate Number: 72-R-0007). Four monkeys of ages 6.9-7.8 years old and body weights 7.7-10.6 kg and 4 monkeys of ages from 10.0-15.6 and body weights from 7.6-8.3 kg, respectively, at time of dosing were selected for the studies. Animals were tested for enteric parasites and bacterial pathogens during pre-study physical exams. Monkeys were acclimatized to their designated housing for at least 3 days prior to the dosing and were chair trained prior to study initiation. Animals were observed twice daily throughout the study for changes in general appearance and behavior and daily for signs of adverse effects. The animals were single housed for the duration of the study. In order to reduce confounding effects, animals were dosed in a consistent order (for aldesleukin daily dosing) and blood samples were collected at specified timepoints relative to the timing of dose administration for each animal. These studies were reviewed and approved by university of Louisiana Lafayette’s Animal Care and Use Committee (IACUC approval number 2019-8713-016) prior to the study. During the study, the care and use of animals were conducted in accordance with the regulations of the USDA Animal Welfare Act (i.e., relevant sections of Section 9, Parts 1, 2 and 3 of the Code of Federal Regulations).

The second monkey study testing different dose levels of TransCon IL-2 β/γ was performed at Labcorp Early Development Laboratories Ltd Harrogate, UK (Project License Number: P98E2EBFD). Six monkeys were allocated from the stock colony in order to provide 3 healthy animals of each sex. At the start of dosing, animals were 111 to 130 weeks old and weighed
between 2.46 and 3.69 kg. All animals were tested for tuberculosis while at the premises of the breeder. Upon arrival, all animals were given a clinical inspection for ill health and tested for tuberculosis. Animals were acclimated to the facility for 13 to 20 weeks and to the study room for 2 to 4 weeks. A veterinary inspection was performed before the start of dosing to ensure suitability for the study. Animals were housed in pens that conform to the Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes (Home Office, 2014). Animals of the same sex were housed in the same pen. Animals were observed at least twice daily. Medical treatment necessary to minimize suffering and distress, including euthanasia, was the responsibility of the attending licensed animal technicians and/or Veterinary Surgeons. This study was approved by the Animal Welfare Ethical Review Body (AWERB) for Labcorp Harrogate (Study Reference: 8448706) and was performed in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986.

**Flow cytometry and cytokine analysis in cynomolgus monkeys**

Peripheral blood taken from study animals was lysed (PharmLyse) and stained for surface markers (CD3, CD4, CD8, CD159, CD14, CD25, CD28, and γδ TCR) before fixation and permeabilization (eBiosciences Foxp3 kit) and staining for intracellular markers (Ki67, Granzyme B and Foxp3). Cells were also stained with counting beads (Invitrogen) for assessment of absolute counts.

No prespecified quality metrics were defined for exclusion or flow cytometry data however post data acquisition analysis revealed some likely technical outliers due to failed intracellular staining processes which were excluded from analysis by the contract service laboratory performing the experiment. Specifically, the FoxP3 and Ki67 results at 168 and 336 hours postdose for animals receiving 0.9 mg/kg were excluded from analysis due to a possible error in the intracellular staining of these two markers.
Table SM 3A: Reagents used in Cynomolgus Monkey flow cytometry analysis

| Marker / Reagent | Color    | Cat.    | Clone | Vendor         |
|------------------|----------|---------|-------|----------------|
| CD3              | BV605    | 562994  | SP34-2| BD             |
| CD4              | BV711    | 563913  | L200  | BD             |
| CD8              | AF700    | 344724  | SK1   | Biolegend      |
| CD14-BUV737      | BD       | 612763  | M5E2  | Bioscience     |
| CD25             | BUV395   | 564034  | 2A3   | BD             |
| CD28             | PE-Cy5   | 555730  | CD28.2| BD             |
| CD45             | BV786    | 563861  | 058-1283| BD          |
| CD95             | BV421    | 562616  | DX2   | BD             |
| CD159a (NKG2A)   | PC7      | B10246  | Z199  | Beckman Coulter|
| Foxp3            | PE       | 560046  | 259D/C7| BD            |
| Granzyme B       | AF647    | 560212  | GB11  | BD             |
| KI67             | FITC     | 556026  | B56   | BD             |
| TCR γ/δ          | APC/FIRE™750 | 331228 | B1    | Biolegend     |
| mouse-IgG1       | PE       | 555749  | MOPC-21| BD          |
| TCR Vδ2          | BV421    | 331428  | B6    | Biolegend     |
| TCR Vγ9          | PE-Cy7   | 331320  | B3    | Biolegend     |

Table SM 3B: Populations analyzed in Cynomolgus monkey flow cytometry data

| Population               | Gating Definition                      |
|--------------------------|----------------------------------------|
| Lymphocytes              | CD14-CYCD45+                           |
| T cells                  | CD14-CYCD45+CD3+                       |
| CD4+ T cells             | CD14-CYCD45+CD3+CD4+                   |
| Tregs                    | CD14-CYCD45+CD3+CD4+CD25+Foxp3+       |
| CD8+ T cells             | CD14-CYCD45+CD3+CD8+                   |
| γδ T cells               | CD14-CYCD45+CD3+CD4-CD8-γδTCR+         |
| NK cells                 | CD14-CYCD45+CD3-NKG2A+                 |
| Naïve CD4+ T cells       | CD14-CYCD45+CD3+CD4+CD28+CD95-        |
| Naïve CD8+ T cells       | CD14-CYCD45+CD3+CD8+CD28+CD95-        |
| Central memory CD4+ T cells | CD14-CYCD45+CD3+CD4+CD28+CD95+    |
| Central memory CD8+ T cells | CD14-CYCD45+CD3+CD8+CD28+CD95+    |
| Effector memory CD4+ T cells | CD14-CYCD45+CD3+CD4+CD28-CD95+   |
| Effector memory CD8+ T cells | CD14-CYCD45+CD3+CD8+CD28-CD95+   |

Serum levels of IL-5, IL-6, IFN-γ and MCP-1 were measured using an ELISA/Multiplex methods using the Luminex 100 platform and BioPlex 200 software. Serum TNF-α was detected using the MSD U-Plex non-human primate TNF-α Kit and an MSD Sector Imager 600. Detection of serum
sCD25 was performed using the R&D Systems Quantikine Human CD25/IL-2Rα ELISA Kit and a SpectraMax i3x.

**Anatomical Pathology**

An anatomical pathology examination was performed by a board-certified pathologist at Labcorp. Approximately 50 organs and tissues were examined, including lung, kidney, liver, spleen, brain, heart, various lymph nodes and lymphoid tissues, nerves, reproductive organs and organs of the digestive system. Organ weights and macroscopic observations were recorded, and histopathology was performed to assess microscopic changes. In the absence of a control group, all findings were compared to historical control data from this laboratory.

**In vitro human lymphocyte cytotoxicity and cytokine assays**

Human PBMCs were purified from Leukoreduction chambers by Ficoll density centrifugation (GE Healthcare) and used to purify NK cell (average 93% purity), CD8+ T cell (average 87% purity overall with 92% purity within T cells), or γδ T cell (average 78% purity overall with 98% purity within T cells) populations using negative selection kits (EasySep™ Human NK Cell Isolation Kit, EasySep™ Human CD8+ T Cell Isolation Kit, and EasySep™ Human Gamma/Delta T Cell Isolation Kit from StemCell Technologies; and TCRγ/δ+ T Cell Isolation Kit, human, from Miltenyi Biotec).

NK cell cytotoxicity assays used K562 erythroleukemia target cells. Briefly, 5,000-10,000 labeled (BATDA loaded) K562 cells were incubated with NK cells at Effector to Target (E:T) ratios from 5 to 0.78 for 4 h at 37°C, together with 1.25 mM probenecid to promote BATDA retention. Maximum release was determined by lysing target cells using 0.1% Triton X-100. Specific lysis
was calculated as (experimental release – spontaneous release) / (maximum release - spontaneous release).

CD8\(^+\) T cytotoxicity assays used Raji target cells (ATCC) in the presence of 1 nM of a CD3-CD20 bispecific antibody (Creative BioLabs) in a flow cytometry assay. Briefly, 10,000 Raji cells, marked with 50 nM CellTrace Far Red (CTFR, Invitrogen), were co-incubated with various concentrations of CD8\(^+\) T cells at E:T ratios from 10 to 0.16 overnight at 37\(^\circ\)C. All cells were stained with Fixable Viability Dye eFluor 506 (Invitrogen) and analyzed by flow cytometry. The percentage of dead target cells was determined within CTFR\(^+\) Raji cells.

Cytotoxicity of \(\gamma\delta\) T cells was evaluated against Raji target cells as described above and also evaluated using CTFR labeled Daudi target cells (ATCC), both at E:T ratios ranging from 8 to 0.125. The percentage of dead target cells was determined within CTFR\(^+\) Raji or Daudi cells. For Daudi assays, due to some donors showing high spontaneous death, the background from conditions with Daudi alone were subtracted to visualize IL-2 \(\beta/\gamma\) induced cytotoxicity.

Additionally, supernatants from the above cytotoxicity conditions were analyzed for TNF-\(\alpha\), IFN-\(\gamma\), IL-17A FasL, Granzyme A, Granzyme B, Granulysin and Perforin concentrations via LegendPlex (Biolegend) detection reagents using a Quanteon flow cytometer.
Supplemental Results

Anatomical Pathology

For the lungs, there were no organ weight changes, no macroscopic findings and no microscopic findings in any of the animals, indicative of no pulmonary edema. Further, histopathological examination did not reveal vascular damage or tissue necrosis in any of the tissues examined in any of the animals, supporting that TransCon IL-2 β/γ does not induce VLS.